Kaposi's sarcoma (KS) as the most common AIDS-associated malignancy is etiologically caused by KS-associated herpesvirus (KSHV). KS is a highly disseminated and vascularized tumor. KSHV encodes 12 pre-microRNAs that yield 25 mature microRNAs (miRNAs), but their roles in KSHV-induced tumor metastasis and angiogenesis remain largely unclear. KSHV-encoded miR-K12-6 (miR-K6) can generate two mature miRNAs, miR-K6-5p and miR-K6-3p. Recently, we have shown that miR-K6-3p induced cell migration and angiogenesis via directly targeting SH3 domain binding glutamate-rich protein (SH3BGR). Here, by using mass spectrometry, bioinformatics analysis and luciferase reporter assay, we showed that miR-K6-5p directly targeted the coding sequence of CD82 molecule (CD82), a metastasis suppressor. Ectopic expression of miR-K6-5p specifically inhibited the expression of endogenous CD82 and strongly promoted endothelial cells invasion and angiogenesis. Overexpression of CD82 significantly inhibited cell invasion and angiogenesis induced by miR-K6-5p. Mechanistically, CD82 directly interacted with c-Met to inhibit its activation. MiR-K6-5p directly repressed CD82, relieving its inhibition on c-Met activation and inducing cell invasion and angiogenesis. Lack of miR-K6 abrogated KSHV suppression of CD82 resulting in compromised KSHV activation of c-Met pathway, and KSHV induction of cell invasion and angiogenesis. In conclusion, our data show that by reducing CD82, KSHV miR-K6-5p expedites cell invasion and angiogenesis by activating the c-Met pathway. Our findings illustrate that KSHV miRNAs may be critical for the dissemination and angiogenesis of KSHV-induced malignant tumors.
INTRODUCTION
Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus involved in the development of several human malignancies, such as Kaposi's sarcoma (KS). 1 KS is a tumor of vast angiogenesis expressing mixed cellular markers. 2 It is characterized by abnormally dense and irregular blood vessels, and vast inflammatory infiltration, as well as an abundance of growth factors (GFs), inflammatory cytokines (ICs), angiogenic factors and invasive factors. 3 These cytokines and factors, including angiogenin, vascular endothelial growth factor (VEGF), matrix metalloproteinases (MMPs) and tumor necrosis factor-α, may promote the angiogenic phenotype in KS lesions [4] [5] [6] and contribute to the dissemination of KS involving visceral organs. 7, 8 Like other herpesviruses, KSHV life cycle consists two phases, there are latency and lytic replication. During latency, some genes, which are essential for KSHV-induced tumorigenesis are expressed. Besides these latent proteins, KSHV genome also encodes 12 precursor microRNAs (pre-miRs) further processed into 25 mature miRNAs, all of them are expressed at a high level in KS tumors as well as during KSHV latency. 1, [9] [10] [11] [12] [13] [14] MiRNAs are small non-coding RNA molecules that posttranscriptionally repress gene expression via binding to the 3'-untranslated regions (UTRs) or coding sequence (CDS) of mRNAs. 15 The KSHV miRNAs regulate viral lytic reactivation, apoptosis, cell cycle, immune evasion, angiogenesis and epigenetic regulation by targeting viral and/or host genes. 16 For instance, miR-K4, miR-K5 and miR-K9-5p, as well as miR-K3 and miR-K7-5p have been demonstrated to maintain latency by directly or indirectly targeting RTA, a KSHV lytic switch protein. [17] [18] [19] [20] MiR-K1 maintains nuclear factor-κB-dependent viral latency by targeting NF-kappa-B inhibitor alpha. 21 In addition, miR-K9 targets interleukin-1 receptor-associated kinase 1 to mediate toll-like receptor/interleukin (IL)-1 receptor signaling, thus leading to reduced inflammation; MiR-K5 also regulates tolllike receptor/interleukin (IL)-1 receptor pathway by regulating myeloid differentiation primary response protein 88 (MYD88). 22 Moreover, miR-K3 and miR-K7 inhibit CCAAT/enhancer-binding protein β expression, which is a transcriptional repressor of interleukin-10 and interleukin-6, to promote cell growth and angiogenesis. 23, 24 Our recent work showed that miR-K3 induced cell migration, invasion and angiogenesis and enhanced viral latency by targeting G protein-coupled receptor kinase 2, modulating C-X-C motif chemokine receptor 2/AKT signaling pathway. 25, 26 We also found that miR-K6-3p activated signal 1 transducer and activator of transcription 3 pathway by directly targeting SH3BGR, and then contributed to cell migration and angiogenesis. 27 Although several functions of KSHV miRNAs have been revealed, their roles in the development of KSHV-induced malignant tumors, especially in KSHV-induced tumor metastasis and angiogenesis, remain unclear.
CD82, a metastasis suppressor, was widely used in predicting metastatic potential of variety solid malignant tumors as a biomarker. 28 CD82 was also reported to have an effect on tumor growth except for suppressing tumor metastasis 29, 30 and regulate various cellular functions, such as cell adhesion, movement, senescence and survival. [31] [32] [33] [34] [35] [36] [37] [38] Despite the fact that CD82 restrains cancer metastasis, its role in the pathogenesis of KS remains unknown.
KSHV miR-K6 is processed into two mature miRNAs, miR-K6-5p and miR-K6-3p, which are exhibited at a high level in KS tumors 39 and latent KSHV infection of B cells. 40 MiR-K6-3p has been demonstrated to expedite endothelial cell migration and angiogenesis, implying that miR-K6-5p may also be conducive to the development of KS tumors. In present work, we seeked to monitor the role of miR-K6-5p in cell mobility and angiogenesis. We observed that miR-K6-5p expedited cell invasion and angiogenesis via directly targeting the CDS of CD82. In addition, c-Met activation was demanded of cell invasion and angiogenesis induced by miR-K6-5p, which was suppressed by CD82. Our findings provide further insights into the molecular mechanism of KSHV miRNAs, which are beneficial for the pathogenesis of KSHVinduced malignant tumors.
RESULTS

miR-K6-5p expression increases endothelial cell invasion and angiogenesis
We previously reported that KSHV miR-K6-3p contributed to cell migration and angiogenesis by regulating the SH3BGR/signal transducer and activator of transcription 3 pathway. 27 Considering that miR-K6-5p was rooted in the same pre-miR with miR-K6-3p, we wondered whether miR-K6-5p could also contribute to tumor metastasis and angiogenesis induced by KSHV. To address this issue, we first transduced human umbilical vein endothelial cells (HUVECs) with lentivirus-expressing miR-K6-5p ( Figure 1a ), and ulteriorly executed luciferase reporter assay to monitor whether the miR-K6-5p expression construct was functional in HUVECs. We observed that miR-K6-5p prominently suppressed the pGL3-miR-K6-5p sensor reporter activity ( Figure 1b ). Then, transwell migration and Matrigel invasion assays were adopted to examine whether miR-K6-5p had any effect on cell motility. As shown in Figures 1c and d, ectopic expression of miR-K6-5p markedly enhanced cell invasion when compared with control cells. However, miR-K6-5p had no effect on cell migration (Supplementary Figure S1 ). We conducted a tubule formation assay to monitor the influence of miR-K6-5p on angiogenesis, and Figure 1 . miR-K6-5p expression increases cell invasion and angiogenesis in vitro. (a) Lentivirus-miR-K6-5p and lentivirus empty vector were used to transduce HUVECs, and representational images were photographed using a fluorescence microscope (×100). (b) Lentivirus-miR-K6-5p-or mpCDH-transduced HUVECs were transfected with the pGL3-miR-K6-5p sensor reporter (Sensor) or its control (Control) and then were used for luciferase activity. (**P o0.01). (c) Matrigel invasion assay was adopted in HUVECs treated as delineated in a. The representational images were photographed 6 or 12 h after seeding (×100). (d) Quantitative analysis of Matrigel invasion assay in c. Mean ± s.d. is adopted to quantify the results. Three independent experiments, each with quintic technical replicates, were performed. (e) Lentivirus-miR-K6-5ptransduced or mpCDH-transduced HUVECs were applied for tubule formation assay. The representational images were photographed using a fluorescence microscope 2 or 5 h after seeding (×100). (f) Quantitative analysis of microtubule formation assay in e. Mean ± s.d. is adopted to quantify the results. (g) RT-qPCRs were used to monitor the mRNA levels of MMP10 and VEGFA expressed in HUVECs treated as in a. Mean ± s.d. is adopted to quantify the results (***Po0.001).
observed that miR-K6-5p expression strikingly enhanced formation of capillary tubes in HUVECs (Figures 1e and f) . Moreover, expression of miR-K6-5p elevated the levels of MMP10 and vascular endothelial growth factor A (VEGFA) mRNA transcripts (Figure 1g ), which are known to promote cell invasion and angiogenesis.
We further determined the influence of miR-K6-5p on angiogenesis induced by KSHV in an in vivo chick chorioallantoic membrane (CAM) angiogenesis model. Expression of miR-K6-5p increased the angiogenesis index (Figures 2a and b) . We also performed an in vivo Matrigel plug angiogenesis assay to confirm these observations. Hemoglobin of the plugs was strikingly increased with miR-K6-5p overexpression ( Figures 2c and d and Supplementary Figure S2 ). Hematoxylin and eosin staining exhibited abnormally dense neovascularization along with erythrocyte infiltration in plugs of HUVECs infected with miR-K6-5p Figure 2 . miR-K6-5p expression promotes cell angiogenesis in vivo. (a) Lentivirus-miR-K6-5p-transduced or mpCDH-transduced HUVECs were adopted to evaluate the pro-angiogenic effects of miR-K6-5p in a CAM model. Representational graphs of angiogenesis are shown. (b) Results were quantified in a. Mean ± s.d. is adopted to quantify the results, each group with at least five tumors. (**Po0.01). (c) Matrigel plug assay was adopted in HUVECs treated as described in a. Representational photographs of plugs are exhibited. (d) The levels of hemoglobin in the Matrigel plugs treated as in c was measured by comparing with the standard curve. Mean ± s.d. is adopted to quantify the results, with at least five tumors for each group. (***P o0.001). (e) Representative panels showed the histologic features (hematoxylin and eosin) and the expression of smooth muscle actin (SMA), VEGFA and basic fbroblast growth factor in plugs induced by mpCDH-infected or miR-K6-5pinfected HUVECs (immunohistochemistry) (×400). The new formed blood vessels and the SMA expression were pointed out by black arrows, respectively. (f) Results were quantified in e. (***P o0.001). (g) RT-qPCRs were used to detect the levels of MMP10 and VEGFA mRNA expressed in the Matrigel plugs treated as in c. Mean ± s.d. is adopted to quantify the results. (**Po 0.01 and ***P o0.001).
( Figure 2e ). We then examined the levels of smooth muscle actin, as well as VEGFA and basic fibroblast growth factor, both are proangiogenic factors by immunohistochemistry. As shown, there were more SAM-, VEGFA-and basic fibroblast growth factorpositive cells in the miR-K6-5p plugs (Figures 2e and f) . Consistently, the expression of MMP10 and VEGFA on mRNA levels were distinctly enhanced in the miR-K6-5p plugs ( Figure 2g ). These data indicated that miR-K6-5p was beneficial for cell invasion and angiogenesis.
miR-K6-5p expedites cell invasion and angiogenesis by directly targeting the CDS of CD82 gene
To identify the targets that mediate cell invasion and angiogenesis induced by miR-K6-5p, we conducted mass spectrometry analysis to detect proteins differentially expressed in mpCDH-and miR-K6-5p-transduced HUVECs. Among the downregulated cellular proteins (Table 1) , bioinformatics analysis identified five proteins that had miR-K6-5p predicted targeting sites in their 3'-UTR or CDS ( Table 2 ). Luciferase reporter assay indicated that both CD82 and B4GALT5 CDS reporter activities were suppressed by miR-K6-5p ( Figure 3a ). However, miR-K6-5p can only reduce CD82 protein expression ( Figure 3b ), which was chosen for further validation. Moreover, the mRNA level of CD82 was strikingly downregulated in HUVECs transduced with miR-K6-5p ( Figure 3c ). Meanwhile, KSHV infection distinctly reduced CD82 protein expression, as well as its mRNA level (Figures 3d and e ). Consistently, the positive cells of CD82 in KS lesion were less than the normal skin tissue (Figures 3f and g). Figure 4a , miR-K6-5p reduced the CD82 CDS reporter activity in a dose-dependent manner. Western blotting and reverse transcriptase (RT)-quantitative PCR (qPCR) exhibited that CD82 expression was suppressed by miR-K6-5p in a dosedependent manner (Figures 4b and c). To examine whether miR-K6-5p directly targeted CD82, we performed co-transfection of miR-K6-5p mimics along with a CD82 expression plasmid and a pEGFP-N2 plasmid into HUVECs and HEK293T cells, respectively. Western blotting indicated that the expression of exogenous CD82 was markedly inhibited by miR-K6-5p in a dose-dependent manner but not that of enhanced green fluorescent protein, which was used as a control for transfection efficiency (Figure 4d ).
As shown in
To further demonstrate that CD82 is the direct target of miR-K6-5p, we performed mutagenesis with the CD82 CDS reporter and miR-K6-5p ( Figure 4e ). MiR-K6-5p did not have any influence on the mutant CD82 CDS reporter activity, and the mutant mimic rendered it ineffective in inhibiting the CD82 CDS reporter activity ( Figure 4f ). The mutant mimic strongly inhibited the mutant CDS reporter activity ( Figure 4f ). Consistent with these results, miR-K6-5p mimic suppressed CD82 expression in HUVECs, whereas mutant miR-K6-5p mimic did not ( Figure 4g ). HUVECs transfected with miR-K6-5p had similar expression level of CD82 protein to that infected by KSHV ( Figure 4h ). These results indicated that CD82 was the direct target of miR-K6-5p.
To monitor the role of CD82 in cell invasion and angiogenesis induced by miR-K6-5p, we transduced lentivirus-CD82 into miR-K6-5p-expressing HUVECs, and followed by analyzing for the activities of cell invasion and angiogenesis. Overexpression of CD82 distinctly blocked miR-K6-5p-induced invasion 6 and 12 h 
Abbreviation: HUVEC, human umbilical vein endothelial cell. Figure S3 ). Consistently, overexpression of CD82 suppressed the levels of MMP10 and VEGFA transcripts in plugs of HUVECs transduced with miR-K6-5p ( Figure 5k ).
Suppression of CD82 activates the c-Met signaling, which mediates cell invasion and angiogenesis induced by miR-K6-5p
It has been reported that CD82 blocked the interaction of integrin and c-Met, as well as integrin-dependent interaction of Src and c-Met to inhibit the HGF receptor c-Met, leading to reduction of invasion and growth of cells. 41, 42 c-Met and CD82 were also demonstrated to colocalize and form a complex at the cell periphery. 43 Given these findings, we assumed that c-Met may also contribute to CD82-mediated miR-K6-5p-induced cell invasion and angiogenesis. Indeed, KSHV latently infected HUVECs had increased the level of c-Met phosphorylation. 44 Importantly, ectopic expression of miR-K6-5p alone was sufficient to enhance c-Met phosphorylation (Supplementary Figure S4a ). Overexpression of CD82 in miR-K6-5p-expressing HUVECs reduced c-Met activation (Supplementary Figure S4b Figure S4g ). In addition, knockdown of CD82 with short hairpin RNAs (shRNAs) elevated the phosphorylated c-Met level ( Supplementary Figures S4g and 5) . These data indicated that CD82 directly interacted with c-Met to suppress its activation, and miR-K6-5p directed inhibition of CD82 to relieve its repression of activated c-Met, leading to higher level of c-Met activation. Next, we explored whether c-Met activation was necessary for cell invasion and angiogenesis induced by miR-K6-5p. As expected, knockdown of c-Met expression by transduction of a mixture of shRNAs (shc-Met; Figure 6a and Supplementary Figure S6 Lack of miR-K6 restrains cell invasion and angiogenesis induced by KSHV Before this work, we have already discovered that the deleted gene encoding miR-K6 from KSHV genome inhibited cell migration and tube formation induced by KSHV. 27 Here, we found that deleted miR-K6 also decreased the levels of cell invasion (Figures 7a and b) . Importantly, CD82 expression was increased and c-Met phosphorylation was reduced in the miR-K6-mutant virus-infected cells in comparison with wild-type KSHV-infected cells (Figure 7c ). As we previously showed, the mutant virus- Figure 5 . Overexpression of CD82 compromises cell invasion and angiogenesis induced by miR-K6-5p. (a) Matrigel invasion assay was adopted in lentivirus-mpCDH-or miR-K6-5p-infected HUVECs, followed by transduction with lentivirus-CD82 (CD82) or its control pHAGE (pHAGE), respectively. Representative photographs were taken 6 or 12 h after seeding (×100). (b) Results were quantified in a. Mean ± s.d. is adopted to quantify the results. (*P o0.05 and ***P o0.001). (c) Tubule formation assay was adopted in HUVECs treated as described in a. Representative photographs were taken 2 or 5 h after seeding (×100). (d) Results were quantified in c. Mean ± s.d. is adopted to quantify the results. (*P o0.05 and **Po0.01). (e) The levels of MMP10 and VEGFA mRNA expressed in HUVECs treated as described in a were measured by qPCR. Mean ± s.d. is adopted to quantify the results. (**P o0.01 and ***P o0.001). (f) Western blotting was adopted in HUVECs treated as in a with the indicated antibodies. (g) CAM assay was adopted in HUVECs treated as described in a. Representative photographs of angiogenesis are presented. (h) Results were quantified in g. Mean ± s.d. is adopted to quantify the results, each group with at least five tumors. (i) Matrigel plug assay was adopted in HUVECs treated as described in a. Representative photographs of plugs are exhibited. (j) The level of hemoglobin in the Matrigel plugs treated as described in i was measured by referring to the standard curve. Mean ± s.d. is adopted to quantify the results, with six tumors (n = 6) for each group. (k) The levels of MMP10 and VEGFA mRNA expressed in the Matrigel plugs treated as described in i were measured by using qPCR. Mean ± s.d. is adopted to quantify the results. (*Po 0.05, **Po0.01 and ***P o0.001). Figure 6 . Inhibition of CD82 activates the c-Met signaling, which mediates cell invasion and angiogenesis induced by miR-K6-5p (a). Western blotting was adopted to measure level of phosphorylated c-Met in lentivirus-miR-K6-5p-or mpCDH-infected HUVECs, followed by transduction with lentivirus expressing a mixture of shRNAs targeting c-Met (shc-Met). (b) Matrigel invasion assay was adopted in HUVECs treated as described in a. Mean ± s.d. is adopted to quantify the results. (*P o0.05 and **Po 0.01). (c) Tubule formation assay was adopted in HUVECs treated as described in a. Mean ± s.d. is adopted to quantify the results. (*P o0.05, **Po 0.01 and ***Po0.001). (d) The levels of MMP10 and VEGFA mRNA expressed in HUVECs treated as in a were measured by qPCR. Mean ± s.d. is adopted to quantify the results. (*Po 0.05 and **Po0.01). (e) Matrigel plug assay was adopted in HUVECs treated as described in a. The levels of hemoglobin in the Matrigel plugs were measured by referring to the standard curve. Mean ± s.d. is adopted to quantify the results, with six tumors for each group. (f) The levels of MMP10 and VEGFA mRNA expressed in the Matrigel plugs treated as described in e were measured by using qPCR. Mean ± s.d. is adopted to quantify the results. (*Po 0.05 and **P o0.01). (g) Western blotting was adopted to examine levels of phosphorylated c-Met and total c-Met in lentivirus-miR-K6-5p-infected or mpCDH-infected HUVECs followed by treatment with the c-Met inhibitor, PF-2341066 (PF-2341066) or its control (DMSO). (h) Matrigel invasion assay was adopted in HUVECs treated as described in g. Mean ± s.d. is adopted to quantify the results. (*P o0.05 and **Po0.01). (i) Tubule formation assay was adopted in HUVECs treated as described in g. Mean ± s.d. is adopted to quantify the results. (*P o0.05 and **Po 0.01).
microscope (Supplementary
CD82/c-Met axis and angiogenesis by a viral miRNA W Li et al infected cells had a reduced level of VEGFA. Compared with wildtype KSHV-infected cells, those mutant virus-infected cells also had a decreased level of MMP10 mRNA but an increased level of CD82 mRNA (Figure 7d ). Furthermore, inhibition of miR-K6-5p by transfecting a specific inhibitor into wild-type KSHV-infected HUVECs reduced cell invasiveness and the extent of angiogenesis (Supplementary Figure S7) . Interestingly, c-Met activation was elevated in mutant cells following by knockdown of CD82 with a mixture of shRNAs (Figure 8a and Supplementary Figure S5) , and cell invasiveness and the extent of angiogenesis were partially increased (Figures 8b and c) . Consistent with these results, overexpression of c-Met in mutant cells enhanced cell invasion and angiogenesis (Figures 8d-f ). Overexpression of miR-K6-5p in the mutant cells also enhanced cell invasion and angiogenesis (Supplementary Figure S8 ).
Together, our findings suggested that miR-K6-5p increased cell invasion and angiogenesis by repressing CD82 to activate the c-Met pathway.
DISCUSSION
CD82, a protein of 267 amino acids belonging to tetraspanin superfamily, is a type III transmembrane protein, which is widely distributed in normal tissues. 28 CD82 contains four transmembrane domains, a large extracellular loop, an N and a C cytoplasmic domain, a small intercellular and an extracellular loop. 31 The transmembrane domains contain three highly conserved polar residues, an Asn, a Gln and a Glu polar residue; they bind to each other, as well as interact with transmembrane domains of other tetraspanins. 45 CD82 was reported to suppress metastasis in various solid malignant tumors, for instance, colon, gastric, hepatocarcinoma, thyroid and breast cancers. 46 However, whether CD82 expression was beneficial for the development of KS remains undefined. In present research, we found that CD82 expression in KS tumors was lower than normal skin tissues. We also showed that KSHV infection reduced CD82 expression. In addition, KSHV miR-K6-5p directly targeted CD82 to suppress its expression. MiR-K6-5p reduced the expression of metastasis suppressor CD82, and induced cell invasion and angiogenesis, which may be beneficial for the development and progression of KS.
c-Met, encoded by proto-oncogene Met, is occurred mostly in endothelial and epithelial cells. 47 c-Met is overexpressed in various human tumors, for instance, thyroid, gastric, pancreatic, breast, prostate, cervical and endometrial cancers. [48] [49] [50] [51] [52] [53] [54] c-Met is not only regarded as the receptor for scatter factor, but also perceived as the unique high-affinity receptor for hepatocyte growth factor (HGF). 55, 56 Upon binding with HGF, c-Met activates a great variety of pathways, including those involved in regulating tumor invasion, metastasis and angiogenesis. 57 A previous study reported that KSHV activates the HGF/c-Met pathway in vitro and or miR-K6-mutant virus (miR-K6_Mut) followed by transduction with lentiviruses expressing a mixture of shRNAs targeting CD82 (shCD82). (b) Matrigel invasion assay was adopted in HUVECs treated as described in a. Mean ± s.d. is adopted to quantify the results. (*Po0.05 and **Po0.01). (c) Tubule formation assay was adopted in HUVECs treated as described in a. Mean ± s.d. is adopted to quantify the results. (*Po0.05, **Po0.01 and ***Po0.001). (d) Western blotting was adopted to examine levels of phosphorylated c-Met and total c-Met in HUVECs infected with wild-type KSHV (KSHV_WT) or miR-K6mutant KSHV (miR-K6_Mut), followed by transfection with pCMV3-Flag-c-Met construct (c-Met) or its control (pCMV). (e) Matrigel invasion assay was adopted in HUVECs treated as described in d. Mean ± s.d. is adopted to quantify the results. (*Po0.05 and **Po0.01). (f) Tubule formation assay was adopted in HUVECs treated as described in d. Mean ± s.d. is adopted to quantify the results. (*Po0.05, **Po0.01 and ***Po0.001). (g) Schematic illustration of the mechanism, which miR-K6-5p uses to promote cell invasion and angiogenesis. CD82 binds to c-Met resulting in inhibition of c-Met activation in normal endothelial cells. During KSHV infection, miR-K6-5p targets and inhibits CD82 expression releasing c-Met from CD82 inhibition, leading to c-Met activation, and ultimately promotes endothelial cell invasion and angiogenesis. CD82/c-Met axis and angiogenesis by a viral miRNA in vivo. A c-Met inhibitor induced apoptosis of KSHV-positive primary effusion lymphoma cells and effectively suppressed primary effusion lymphoma tumor progression in vivo via increasing cell cycle arrest and DNA damage. 44 These reports imply that the c-Met signaling may be a potential therapeutic target for KSHV-induced tumors. In this report, we found that KSHV latently infected HUVECs had increased level of c-Met phosphorylation. Moreover, miR-K6-5p expression alone in HUVECs was sufficient to induce c-Met activation. Meanwhile, lack of miR-K6 strongly reduced the level of phosphorylated c-Met in WT KSHV-infected HUVECs. Therefore, miR-K6-5p promotes cell invasion and angiogenesis in part by inducing aberrant c-Met signaling during KSHV infection. This work is the first report to illustrate that c-Met activation is vital for the pathogenesis of KS, and uncover a fresh role of c-Met pathway in the dissemination and angiogenesis of KSHV-associated malignant tumors.
It has been demonstrated that CD82 blocked integrindependent interaction between Src kinases and c-Met receptor to suppress integrin-induced invasion. 41 It is also reported that CD82 inhibits phosphorylation of c-Met stimulated by HGF at Y1313 and Y1365. 58 CD82 expression selectively attenuated c-Met signaling by phosphatidylinositol 3-kinase/Akt signaling. 58 CD82 inhibited HGF-dependent c-Met activity by forming a complex with GM2, 42 and CD82 and c-Met could form a complex to attenuate c-Met signaling by reducing the interaction between adapter protein and the c-Met tyrosine residue. 43 These findings suggests that in normal cells, CD82, which presents in highly quantities, binds to c-Met, leading to reduced c-Met activation, hence inhibiting the progression of human tumors. In present work, we showed that KSHV miR-K6-5p suppressed CD82 expression to release c-Met leading to its activation, therefore contributing to KSHV-induced cell invasion and angiogenesis.
Several studies have identified functions of KSHV pre-miR-K6. For example, miR-K6-5p silenced the cellular transcription factor musculoaponeurotic fibrosarcoma oncogene homolog to induce endothelial cell reprogramming, and consequently contributed to KSHV-induced oncogenesis. 59 miR-K6-5p also increased angiogenesis in vitro by targeting breakpoint cluster region. 60 On the other hand, miR-K6-3p, a miRNA rooted in the same pre-miR with miR-K6-5p, inhibited transforming growth factor beta activity by directly suppressing the expression of tumor-suppressor thrombospondin 1 to regulate cell migration, cell adhesion and angiogenesis. 61 In addition, miR-K6-3p contributed to KSHVinduced angiogenesis by regulating SH3BGR/signal transducer and activator of transcription 3 pathway. 27 In present work, we showed that either inhibition of CD82 or overexpression of c-Met partially rescued KSHV-induced cell invasion and angiogenesis. In accordance with the previous studies, our results indicated that besides the CD82/c-Met pathway, pre-miR-K6 may induce cell invasion and angiogenesis by other cellular target genes.
C-Met activation gives rise to the recruitment of effector proteins, one among them is growth factor receptor-bound protein 2. 62 Growth factor receptor-bound protein 2 binding is linked to c-Met downstream signaling pathways, including key components of oncogenic signaling Ras, Rac1 and p21-activated kinase involved in cell proliferation, cytoskeletal rearrangement and motility. 63 MiR-K6-5p has been shown to increase Rac1 activity by repressing breakpoint cluster region expression. 60 In this study, by directly inhibiting CD82 expression, miR-K6-5p may also contribute to activation of Rac1-p21-activated kinase pathway by enhancing c-Met activation (Figure 8g ).
Interestingly, we examined that ectopic expression of miR-K6-5p alone did not affect the activity of cell migration (Supplementary Figure S1) , and in our previous study, miR-K6-3p was shown to have no effect on cell invasion. 27 However, lack of pre-miR-K6 abolished miR-K6-5p signaling, which was sufficient to suppress KSHV-induced cell motility. Therefore, by encoding two synergistic mature miRNAs with different functions, pre-miR-K6 may enhance the dissemination and invasion of KSHV-associated tumors.
It was initially believed that the recognition sequences of miRNAs may be preferentially located in the 3'-UTR of target mRNAs. However, more and more target sites of miRNAs within CDS have been defined in recent studies. 64 Consistently, our results also indicated that miR-K6-5p targeting site is located in the CDS of CD82 rather than 3'-UTR.
In short, we have uncovered that miR-K6-5p directly targeted the CD82/c-Met pathway to induce endothelial cell invasion and angiogenesis (Figure 8g ). The current findings extend the regulatory networks of KSHV miRNAs, as well as their multiple targets. The essential roles of KSHV miRNAs in the dissemination and angiogenesis of KSHV-associated malignancies illustrate that these miRNAs and their regulated proteins and pathways could serve as novel therapeutic targets of KSHV-associated cancers.
MATERIALS AND METHODS
Cell culture HEK293T and iSLK-BAC16 cells were cultivated as previously delineated, as well as iSLK-BAC16△miR-K6 cells. 65 Primary HUVECs were isolated and cultured as previously delineated. 66 HUVECs were used from passages 3 to 6.
Plasmids
His-tagged CD82 was cloned into the transferring plasmid pHAGE-CMV-MCSIzsGreen as previously described. 67, 68 The CD82 CDS and mutant sequence were inserted into the pGL3-Control plasmid (Promega, Madison, WI, USA) to construct the pGL3-CD82 CDS and the mutant CD82 CDS plasmids. The expressing plasmids of miRNA (miR-K6-5p) and the shRNA were constructed as previously described. 27 The sequences of the shRNAs, which were complementary to CD82 and c-Met, could be found in Table 3 . The pCMV3-Flag-c-Met construct and pCMV3-C-Flag construct were provided by Sino Biological Inc. (Beijing, China). The plasmid pEGFP-N2 containing the enhanced green fluorescent protein gene was bought from Clontech (Palo Alto, CA, USA). In this study, mpCDH was used as the control for miR-K6-5p expression construct and all the shRNA expression constructs, whereas pHAGE was applied as the control for pHAGE-CD82 in this study.
Antibodies, reagents, transfection and western blotting
Antibodies against phospho-c-Met (Y1356) was supplied by Abcam (Cambridge, MA, USA). Anti-c-Met and anti-Flag were provided by Cell Signaling Technologies (Beijing, China). Anti-KSHV LANA was supplied by Abcam (Cambridge, MA, USA). 69 Anti-His, anti-GFP and anti-mouse immunoglobulin G were provided by Beyotime Institute of Biotechnology (Nantong, Jiangsu, China). Anti-CD82, anti-GAPDH, anti-basic fbroblast growth factor and anti-α-tubulin were bought from Santa Cruz Biotechnology (Dallas, TX, USA). PF-2341066, a c-Met inhibitor, was supplied by Selleck Chemicals (Shanghai, China). HUVECs were transfected using the Effectence transfection reagent (Qiagen, Suzhou, Jiangsu, China). Western blotting analysis was conducted as previously delineated. 70, 71 Generation of WT or mutant miR-K6 recombinant viruses KSHV BAC16 virus and miR-K6 mutant viruses were generated as previously delineated. 27, 72 
Lentiviral transduction
Lentiviral packing expression plasmids were co-transfected into HEK293T cells to obtain recombinant lentiviruses as previously delineated. 73 The viruses were collected from the culture supernatant 48 h post-transfection.
Cell migration and invasion assays
As it was delineated in the previous studies, cell migration and invasion assays were done. 25, 27 In brief, 1.2 × 10 5 HUVECs were seeded into chamber with or without matrigel coated. After incubation for 6 or 12 h, cells were first fixed, stained, photographed randomly and then counted in a double-blinded manner by two observers.
Reverse transcriptase-quantitative PCR
The isolation of total RNA was done according to the user guide of Trizol reagent (Invitrogen, Shanghai, China). ImProm-II (Promega) was adopted to conduct reverse transcription. qPCR was executed with SYBR Green Mix (TaKaRa Biotechnology Co. Ltd, Dalian, China). PCR primers could be found in Table 4 .
Mass spectrometry analysis
Mass spectrometry analysis was performed by using a standard proteomics workflow as previously delineated. 27 Maxquant (version 1.2.2.5, Max Planck Institute of Biochemistry, Munich, Germany) was adopted to search spectra, and minimum protein probability cutoffs leading to a 1% false discovery rate were used.
Immunohistochemistry
The use of the clinical samples in present work was approved by the Ethics Committee of Jiangsu Province Hospital (# 2015-SR-116, Nanjing, China). The clinical specimens were kindly offered by Jiangsu Province Hospital. All human participants provided informed consent, and all samples were anonymized. Sections for formalin-fixed and paraffin-embedded samples were stained with the specific antibodies as it was delineated in previous studies. 25, 73 By calculating the percentage of positive cells, the relative expression level was reckoned.
CAM assay
As previously described, CAM assay was executed. 67, 68, 74 Briefly, cells mixed with High Concentration Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) were inoculated onto the CAM of 9-day-old embryos through the artificial gas chamber hole. The CAM was harvested and examined under stereomicroscope 4-day after implantation. The calculation of newly formed blood vessels were done in a double-blinded manner by two observers.
Matrigel plug assay
All animal care and procedures were executed on the basis of standards established by Laboratory Animal Management Regulations approved by the State Council of People's Republic of China. Nanjing Medical University Experimental Animal Welfare Ethics Committee approved the animal experiments (# NJMU/IACUC_2013-8-18-01). Matrigel plug assay was done as it was delineated in the previous studies. 67, 74 In brief, 1 × 10 7 cells mixed with High Concentration Matrigel were injected subcutaneously into the flank of 3-to 4-week-old male nu/nu nude mice (15-20 g weight; Animal Core Facility of Nanjing Medical University, Nanjing, China). For all animal studies, animals were randomly selected. Concealed allocation and blinding of outcome assessment were used. No statistical method was used to predetermine sample sizes.
Tubule formation assay
Tubule formation assay was done as it was delineated in our previous studies. 27 Tubule formation ability was calculated by counting the number of sprouting cells, number of connected cells and number of polygon in a double-blind manner by two observers.
Co-immunoprecipitation
A standard protocol was adopted for immunoprecipitation. 27 Briefly, following rinsing, and lysing, cell supernatants were subjected to immunoprecipitation by using specific antibody. The precipitated material was separated and analyzed by immunoblotting.
Confocal microscopy
The immunofluorescence staining was done as previously delineated. 67 In brief, cells were seeded onto the bottom of cell culture dishes, and then fixed, permeabilized, washed and incubated with antibodies against CD82 (Abcam, Cambridge, MA, USA) and phospho-c-Met (Y1356). Alexa Fluro 555-coupled anti-rabbit and Alexa Fluro 488-coupled anti-mouse secondary antibodies were used, respectively. Images were photographed by Carl Zeiss LSM710 confocal microscopy (Carl Zeiss, Freistaat Thü ringen, Germany).
Statistical analysis
All experimental results are exhibited as mean ± s.d. and were repeated at least three times. Statistical analysis was based on chi-square test for Figures 2f and 3g , and two-sided Student's t-test for the remaining figures.
A difference with P-values of o 0.05 was considered statistically significant. MMP10  RT-qPCR  F: 5′-GGACCTGGGCTTTATGGAGATAT-3′  R: 5′-CCCAGGGAGTGGCCAAGT-3′  VEGFA  RT-qPCR  F: 5′-CTTGCCTTGCTGCTCTACCT-3′  R: 5′-GATTCTGCCCTCCTCCTTCT-3′  CD82 RT-qPCR F: 5′-GCTCATTCGAGACTACAACAGC-3′ R: 5′-GTGACCTCAGGGCGATTCA-3′ β-Actin RT-qPCR F: 5′-TTGCCGACAGGATGCAGAAGGA-3′ R: 5′-AGGTGGACAGCGAGGCCAGGAT-3′
Abbreviations: F, forward; qPCR, quantitative PCR; R, reverse; RT, reverse transcriptase.
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